Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15170
UPID:
TCAL1_HUMAN
Alternative names:
Nuclear phosphoprotein p21/SIIR; Transcription elongation factor S-II protein-like 1
Alternative UPACC:
Q15170; Q9UJQ9
Background:
Transcription elongation factor A protein-like 1, also known as Nuclear phosphoprotein p21/SIIR, plays a crucial role in transcriptional regulation. It modulates various viral and cellular promoters in a context-dependent manner, enhancing transcription from the FOS promoter while repressing Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter activity. This protein does not bind DNA directly.
Therapeutic significance:
Linked to a neurodevelopmental disorder characterized by hypotonia, abnormal gait, and intellectual disability, understanding the role of Transcription elongation factor A protein-like 1 could open doors to potential therapeutic strategies.